Bone morphogenetic protein signal transduction in vascular diseases

Bone Morphogenetic Proteins: New Research

Volumn , Issue , 2012, Pages 99-118

  Sánchez Duffhues, Gonzalo ^a   de Vinuesa, Amaya García ^a   ten Dijke, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892045339     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (142)

1. Urist MR. Bone: formation by autoinduction. Science. 1965 Nov 12;150(698):893-9.
2. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988 Dec 16;242(4885): 1528-34.
3. Goumans MJ, Mummery C. Functional analysis of the TGF-ß receptor/Smad pathway through gene ablation in mice. Int JDev Biol. 2000 Apr;44(3):253-65.
4. David L, Feige JJ, Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev. 2009 Jun;20(3):203-12.
5. Lowery JW, de Caestecker MP. BMP signaling in vascular development and disease. Cytokine Growth Factor Rev. 2010 Aug;21(4):287-98.
6. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005 Dec 1; 19(23):2783-810.
7. Schmierer B, Hill CS. TGF-ß-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007 Dec;8(12):970-82.
8. Massague J. TGF-ß in Cancer. Cell. 2008 Jul 25;134(2):215-30.
9. ten Dijke P, Arthur HM. Extracellular control of TGF-ß signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007 Nov;8(11): 857-69.
10. Umulis D, O'Connor MB, Blair SS. The extracellular regulation of bone morphogenetic protein signaling. Development. 2009 Nov;136(22):3715-28.
11. Massague J. TGF-ß signal transduction. Annu Rev Biochem. 1998;67:753-91.
12. Heldin CH, Miyazono K, ten Dijke P. TGF-ß signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997 Dec 4;390(6659):465-71.
13. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-ß family signalling. Nature. 2003 Oct 9;425(6958):577-84.
14. Gilboa L, Nohe A, Geissendorfer T, Sebald W, Henis YI, Knaus P. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol Biol Cell. 2000 Mar;11(3):1023-35.
15. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sei U SA. 1995 Aug 15;92(17):7632-6.
16. Shi Y, Massague J. Mechanisms of TGF-ß signaling from cell membrane to the nucleus. Cell. 2003 Jun 13;113(6):685-700.
17. Feng XH, Derynck R. Specificity and versatility in TGF-ß signaling through Smads. Annu Rev Cell Dev Biol. 2005;21:659-93.
18. Miyazono K, ten Dijke P, Heldin CH. TGF-ß signaling by Smad proteins. Adv Immunol. 2000;75:115-57.
19. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem. 2010 Jan;147(1):35-51.
20. Daly AC, Randall RA, Hill CS. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol. 2008 Nov;28(22):6889-902.
21. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGF-ß/ALK5 signaling. Mol Cell. 2003 Oct;12(4):817-28.
22. Piek E, Afrakhte M, Sampath K, van Zoelen EJ, Heldin CH, ten Dijke P. Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. J Cell Physiol. 1999 Aug;180(2):141-9.
23. Wiater E, Vale W. Inhibin is an antagonist of bone morphogenetic protein signaling. J Biol Chem. 2003 Mar 7;278(10):7934-41.
24. Chan MC, Nguyen PH, Davis BN, Ohoka N, Hayashi H, Du K, et al. A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor. Mol Cell Biol. 2007 Aug;27(16):5776-89.
25. Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord. 2006 Jun;7(1-2):51-65.
26. Kirkbride KC, Ray BN, Blobe GC. Cell-surface co-receptors: emerging roles in signaling and human disease. Trends Biochem Sci. 2005 Nov;30(11):611-21.
27. Scherner O, Meurer SK, Tihaa L, Gressner AM, Weiskirchen R. Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling. J Biol Chem. 2007 May 11;282(19):13934-43.
28. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-ß binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994 Dec;8(4):345-51.
29. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol. 2008;40(3):383-408.
30. Park SH. Fine tuning and cross-talking of TGF-ß signal by inhibitory Smads. J Biochem Mol Biol. 2005 Jan 31;38(1):9-16.
31. Murakami G, Watabe T, Takaoka K, Miyazono K, Imamura T. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell. 2003 Jul;14(7):2809-17.
32. Massague J, Wotton D. Transcriptional control by the TGF-ß/Smad signaling system. EMBOJ. 2000 Apr 17; 19(8): 1745-54.
33. Mulder KM. Role of Ras and Mapks in TGF-ß signaling. Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):23-35.
34. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78.
35. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med. 2000 Oct;6(10):1102-3.
36. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60.
37. Tian M, Neil JR, Schiemann WP. Transforming growth factor-ß and the hallmarks of cancer. Cell Signal. 2011 Jun;23(6):951-62.
38. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005 Dec 15;438(7070):932-6.
39. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001 Feb 1;61(3):253-70.
40. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res. 1996 Oct;32(4):687-98.
41. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res. 2001 Feb 16;49(3):507-21.
42. Bhadada SV, Goyal BR, Patel MM. Angiogenic targets for potential disorders. Fundam Clin Pharmacol. 2011 Feb;25(1):29-47.
43. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008;11(1):79-89.
44. Pardali E, Goumans MJ, ten Dijke P. Signaling by members of the TGF-ß family in vascular morphogenesis and disease. Trends Cell Biol. 2010 Sep;20(9):556-67.
45. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-ß receptor function in the endothelium. Cardiovasc Res. 2005 Feb 15;65(3):599-608.
46. Goumans MJ, Liu Z, ten Dijke P. TGF-ß signaling in vascular biology and dysfunction. Cell Res. 2009 Jan;19(1): 116-27.
47. Bobik A. Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1712-20.
48. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res. 2004 Mar;2(3): 141-9.
49. Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff AK. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene. 2007 Jun 14;26(28):4158-70.
50. Raida M, Heymann AC, Gunther C, Niederwieser D. Role of bone morphogenetic protein 2 in the crosstalk between endothelial progenitor cells and mesenchymal stem cells. Int J Mol Med. 2006 Oct;18(4):735-9.
51. Nakaoka T, Gonda K, Ogita T, Otawara-Hamamoto Y, Okabe F, Kira Y, et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest. 1997 Dec 1;100(11):2824-32.
52. Suzuki Y, Montagne K, Nishihara A, Watabe T, Miyazono K. BMPs promote proliferation and migration of endothelial cells via stimulation of VEGF-A/VEGFR2 and angiopoietin-1/Tie2 signalling. J Biochem. 2008 Feb;143(2):199-206.
53. Kiyono M, Shibuya M. Inhibitory Smad transcription factors protect arterial endothelial cells from apoptosis induced by BMP4. Oncogene. 2006 Nov 16;25(54):7131-7.
54. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005 May 27;96(10): 1053-63.
55. Ren R, Charles PC, Zhang C, Wu Y, Wang H, Patterson C. Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses. Blood. 2007 Apr 1;109(7):2847-53.
56. Valdimarsdottir G, Goumans MJ, Rosendahl A, Brugman M, Itoh S, Lebrin F, et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation. 2002 Oct 22;106(17):2263-70.
57. Ramoshebi LN, Ripamonti U. Osteogenic protein-1, a bone morphogenetic protein, induces angiogenesis in the chick chorioallantoic membrane and synergizes with basic fibroblast growth factor and transforming growth factor-beta1. Anat Rec. 2000 May 1;259(1):97-107.
58. Stabile H, Mitola S, Moroni E, Belleri M, Nicoli S, Coltrini D, et al. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood. 2007 Mar 1;109(5): 1834-40.
59. Lagna G, Nguyen PH, Ni W, Hata A. BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L1059-67.
60. Dorai H, Vukicevic S, Sampath TK. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol. 2000 Jul;184(1):37-45.
61. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci. 2007 Mar 15;120(Pt 6):964-72.
62. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007 Mar 1;109(5):1953-61.
63. Suzuki Y, Ohga N, Morishita Y, Hida K, Miyazono K, Watabe T. BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell Sci. 2010 May 15; 123 (Pt 10): 1684-92.
64. Mallet C, Vittet D, Feige JJ, Bailly S. TGF-ß 1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5. Stem Cells. 2006 Nov;24(11):2420-7.
65. Harradine KA, Akhurst RJ. Mutations of TGF-ß signaling molecules in human disease. Ann Med. 2006;38(6):403-14.
66. Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004 Aug;36(8):855-60.
67. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005 Mar;37(3):275-81.
68. Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, et al. Mutations in transforming growth factor-ß receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation. 2005 Jul 26; 112(4):513-20.
69. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006 Jun;12(6):642-9.
70. Maraire JN, Awad IA. Intracranial cavernous malformations: lesion behavior and management strategies. Neurosurgery. 1995 Oct;37(4):591-605.
71. Abe T, Morishige M, Ooba H, Kamida T, Fujiki M, Kobayashi H, et al. The association between high VEGF levels and multiple probable punctuate cavernous malformations. Acta Neurochir (Wien). 2009 Jul;151(7):855-9.
72. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, et al. Mutations of the TGF-ß type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat. 2006 Feb;27(2): 121-32.
73. Ferns SJ, Wehrmacher WH, Serratto M. Pediatric pulmonary arterial hypertension--a review. Compr Ther. 2009 Summer;35(2):81-90.
74. Zhu P, Huang L, Ge X, Yan F, Wu R, Ao Q. Transdifferentiation of pulmonary arteriolar endothelial cells into smooth muscle-like cells regulated by myocardin involved in hypoxia-induced pulmonary vascular remodelling. Int J Exp Pathol. 2006 Dec;87(6):463-74.
75. Arciniegas E, Servin M, Arguello C, Mota M. Development of the aorta in the chick embryo: structural and ultrastructural study. Atherosclerosis. 1989 Apr;76(2-3):219-35.
76. Arciniegas E, Neves CY, Carrillo LM, Zambrano EA, Ramirez R. Endothelialmesenchymal transition occurs during embryonic pulmonary artery development. Endothelium. 2005 Jul-Aug;12(4):193-200.
77. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005 Aug 16;143(4):282-92.
78. Schluesener HJ, Meyermann R. Immunolocalization of BMP-6, a novel TGF-ß-related cytokine, in normal and atherosclerotic smooth muscle cells. Atherosclerosis. 1995 Mar;113(2):153-6.
79. Yao Y, Watson AD, Ji S, Bostrom KI. Heat shock protein 70 enhances vascular bone morphogenetic protein-4 signaling by binding matrix Gla protein. Circ Res. 2009 Sep 11;105(6):575-84.
80. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993 Apr;91(4):1800-9.
81. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):1998-2003.
82. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation. 2005 May 10;111(18):2364-72.
83. Sorescu GP, Song H, Tressel SL, Hwang J, Dikalov S, Smith DA, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004 Oct 15;95(8):773-9.
84. Mohler ER, 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation. 2001 Mar 20;103(11): 15228.
85. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003 May 6;107(17):2181-4.
86. Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009 Mar 27;104(6):733-41.
87. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010 Dec;16(12):1400-6.
88. Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem. 2003 Nov 14;278(46):45969-77.
89. Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem. 1998 Nov 13;273(46):30427-34.
90. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):489-94.
91. Karsenty G. Minireview: transcriptional control of osteoblast differentiation. Endocrinology. 2001 Jul;142(7):2731-3.
92. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002 Jan 11;108(1):17-29.
93. Brighton CT, Lorich DG, Kupcha R, Reilly TM, Jones AR, Woodbury RA, 2nd. The pericyte as a possible osteoblast progenitor cell. Clin Orthop Relat Res. 1992 Feb(275):287-99.
94. Doherty MJ, Ashton BA, Walsh S, Beresford JN, Grant ME, Canfield AE. Vascular pericytes express osteogenic potential in vitro and in vivo. J Bone Miner Res. 1998 May;13(5):828-38.
95. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008 Nov 4;99(9):1375-9.
96. Boyer AS, Ayerinskas, II, Vincent EB, McKinney LA, Weeks DL, Runyan RB. TGF-ß2 and TGF-ß3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Biol. 1999 Apr 15;208(2):530-45.
97. Lai YT, Beason KB, Brames GP, Desgrosellier JS, Cleggett MC, Shaw MV, et al. Activin receptor-like kinase 2 can mediate atrioventricular cushion transformation. Dev Biol. 2000 Jun 1;222(1):1-11.
98. Camenisch TD, Molin DG, Person A, Runyan RB, Gittenberger-de Groot AC, McDonald JA, et al. Temporal and distinct TGF-ß ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev Biol. 2002 Aug 1;248(1): 170-81.
99. Wang J, Sridurongrit S, Dudas M, Thomas P, Nagy A, Schneider MD, et al. Atrioventricular cushion transformation is mediated by ALK2 in the developing mouse heart. Dev Biol. 2005 Oct 1;286(1):299-310.
100. Okagawa H, Markwald RR, Sugi Y. Functional BMP receptor in endocardial cells is required in atrioventricular cushion mesenchymal cell formation in chick. Dev Biol. 2007 Jun 1;306(1): 179-92.
101. Azhar M, Runyan RB, Gard C, Sanford LP, Miller ML, Andringa A, et al. Ligand-specific function of transforming growth factor beta in epithelial-mesenchymal transition in heart development. Dev Dyn. 2009 Feb;238(2):431-42.
102. Lipton BH, Bensch KG, Karasek MA. Histamine-modulated transdifferentiation of dermal microvascular endothelial cells. Exp Cell Res. 1992 Apr;199(2):279-91.
103. Romero LI, Zhang DN, Herron GS, Karasek MA. Interleukin-1 induces major phenotypic changes in human skin microvascular endothelial cells. J Cell Physiol. 1997 Oct;173(1):84-92.
104. Mironov Y HC, Starcher B, Shin J, Hoffman S, Markwald R. Endothelial-mesenchymal transformation in atherogenesis: a recapitulation of embryonic heart cushion tissue morphogenesis. Ann Biomed Eng 1995;23(S29A).
105. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007 Aug;13(8):952-61.
106. Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007 Jul;293(1):L1-8.
107. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 Nov 18;285(21):1182-6.
108. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003 Jun;9(6):669-76.
109. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996 Aug 9;86(3):353-64.
110. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008 Aug;8(8):592-603.
111. Pardali K, Moustakas A. Actions of TGF-ß as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta. 2007 Jan;1775(1):21-62.
112. Pardali E, ten Dijke P. Transforming growth factor-ß signaling and tumor angiogenesis. Front Biosci. 2009;14:4848-61.
113. Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL, Johnstone D, et al. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer. 1992 Dec;66(6):1159-63.
114. Clement JH, Sanger J, Hoffken K. Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer. 1999 Jan 18;80(2):250-6.
115. Schwalbe M, Sanger J, Eggers R, Naumann A, Schmidt A, Hoffken K, et al. Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. Int J Oncol. 2003 Jul;23(1):89-95.
116. Jin Y, Tipoe GL, Liong EC, Lau TY, Fung PC, Leung KM. Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. Oral Oncol. 2001 Apr;37(3):225-33.
117. Arnold SF, Tims E, McGrath BE. Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: importance of BMP2. Cytokine. 1999 Dec;11(12):1031-7.
118. Clement JH, Marr N, Meissner A, Schwalbe M, Sebald W, Kliche KO, et al. Bone morphogenetic protein 2 (BMP-2) induces sequential changes of Id gene expression in the breast cancer cell line MCF-7. J Cancer Res Clin Oncol. 2000 May;126(5):271-9.
119. Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Buchler MW, et al. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology. 1999 May;116(5):1202-16.
120. Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang WL. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res. 2007 Mar 10;313(5): 1033-44.
121. Bieniasz M, Oszajca K, Eusebio M, Kordiak J, Bartkowiak J, Szemraj J. The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer. 2009 Dec;66(3):319-26.
122. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res. 1997 Oct 1;57(19):4427-31.
123. Masuda H, Fukabori Y, Nakano K, Takezawa Y, T CS, Yamanaka H. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate. 2003 Mar 1;54(4):268-74.
124. Deckers MM, van Bezooijen RL, van der Horst G, Hoogendam J, van Der Bent C, Papapoulos SE, et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology. 2002 Apr; 143(4): 1545-53.
125. Kozawa O, Matsuno H, Uematsu T. Involvement of p70 S6 kinase in bone morphogenetic protein signaling: vascular endothelial growth factor synthesis by bone morphogenetic protein-4 in osteoblasts. J Cell Biochem. 2001;81(3):430-6.
126. Langenfeld EM, Bojnowski J, Perone J, Langenfeld J. Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg. 2005 Sep;80(3):1028-32.
127. Hollnagel A, Oehlmann V, Heymer J, Ruther U, Nordheim A. Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J Biol Chem. 1999 Jul 9;274(28):19838-45.
128. Cunningham NS, Paralkar V, Reddi AH. Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11740-4.
129. White ES, Strom SR, Wys NL, Arenberg DA. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol. 2001 Jun 15;166(12):7549-55.
130. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis. 2003 Sep;24(9):1445-54.
131. Clement JH, Raida M, Sanger J, Bicknell R, Liu J, Naumann A, et al. Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol. 2005 Aug;27(2):401-7.
132. Raida M, Clement JH, Ameri K, Han C, Leek RD, Harris AL. Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int J Oncol. 2005 Jun;26(6):1465-70.
133. Raida M, Clement JH, Leek RD, Ameri K, Bicknell R, Niederwieser D, et al. Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol. 2005 Nov;131(11):741-50.
134. Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res. 2005 Jan 15;65(2):448-56.
135. Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, Goumans MJ, et al. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med. 2010 Jan 18;207(1):85-100.
136. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008 Jan;4(1):33-41.
137. Hong CC, Yu PB. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):409-18.
138. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4388-92.
139. Harth S, Kotzsch A, Hu J, Sebald W, Mueller TD. A selection fit mechanism in BMP receptor IA as a possible source for BMP ligand-receptor promiscuity. PLoS One. 2010;5(9).
140. Kotzsch A, Nickel J, Seher A, Sebald W, Muller TD. Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for GDF-5-type I receptor specificity. EMBO J. 2009 Apr 8;28(7):937-47.
141. Zhang JL, Qiu LY, Kotzsch A, Weidauer S, Patterson L, Hammerschmidt M, et al. Crystal structure analysis reveals how the Chordin family member crossveinless 2 blocks BMP-2 receptor binding. Dev Cell. 2008 May;14(5):739-50.
142. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFss and BMP pathways. Cell Signal. 2011 Nov;23(11):1831-42.